Trinacol

Quick links to important sections

Trinacol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trinacol

Quick Facts

Property Description
Active Ingredients Sulfadiazine, Trimethoprim
Form Oral forms (tablet, powder), Injectable Solution, Oral Suspension
Pharmacological Class Potentiated Sulfonamide Antibiotic
General Purpose Treatment of systemic bacterial infections
Origin Synthetic

Defining Trinacol: A Potentiated Sulfonamide Antibiotic

Trinacol is a synthetic fixed-dose combination (FDC) antimicrobial medication categorized as a Potentiated Sulfonamide Antibiotic. This classification indicates the drug is designed for systemic intervention against bacterial infections. The term potentiated refers to the enhanced efficacy achieved by combining two distinct agents, a strategy recognized for improving treatment outcomes against various pathogens. Products with this identical formulation include Tribrissen and Di-Trim, underscoring its established medical role.

What is the Composition of Trinacol?

Trinacol's core composition features two active pharmaceutical ingredients: Sulfadiazine and Trimethoprim. These agents work sequentially to block the microbial synthesis of folic acid, a necessary compound for bacterial survival and reproduction. This combination provides a broad-spectrum capability against a wide array of susceptible bacteria by interrupting two critical steps in the metabolic pathway. The synergistic nature of this combination characterizes its value as an effective antibacterial compound.

Common Pharmaceutical Forms of Trinacol

To facilitate effective delivery, the active compounds are formulated into various pharmaceutical preparations. Trinacol is available as an injectable solution for parenteral administration, as well as in oral forms like tablets, water-soluble powders, and oral suspensions. This flexibility in form is a key feature, supporting both rapid delivery via injection and sustained delivery via the oral route to ensure the active ingredients are distributed systemically throughout the body.

What side effects are possible with Trinacol?

Possible Side Effects and Safety Information for Trinacol

The safety profile of Trinacol (Sulfadiazine, Trimethoprim) is categorized based on the specific body systems affected and the frequency of occurrence, as outlined in official regulatory documents. Adverse reactions are grouped across several System-Organ Classes (SOCs), including disorders of the gastrointestinal system, the blood and lymphatic system, the skin, the liver, and the kidneys.


Documented Adverse Reactions and Frequency

Common adverse reactions listed in regulatory texts typically involve the gastrointestinal system and the skin, such as nausea, vomiting, loss of appetite, and skin rash. A metabolic effect, hyperkalaemia (high blood potassium), is also frequently documented.

Category Example Reactions
Common Nausea, Vomiting, Skin Rash, Hyperkalaemia
Very Rare Aplastic Anaemia, Hepatic Necrosis, Aseptic Meningitis

Serious Safety Considerations

The label documents the potential for serious adverse reactions, which can be life-threatening. These include severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Fatal disorders of the blood and lymphatic system, such as agranulocytosis and aplastic anaemia, are also officially listed risks. In the event of a skin rash or other signs of a serious reaction, the drug must be discontinued immediately, as required by regulatory mandates.

Population-Specific Safety Notes

Safety constraints are explicitly defined for certain populations. The medicine is contraindicated in infants less than 2 months of age, pregnant patients, and nursing mothers. It is also contraindicated in individuals with documented severe hepatic damage or severe renal insufficiency. Elderly patients are noted in regulatory information as being more susceptible to certain severe adverse reactions and pre-existing kidney or liver impairment.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Trinacol is characterized by the manifestation of specific clinical and physiological signs documented in regulatory labeling.

Documented Presentations and Severe Toxicity

Acute overdose may be indicated by symptoms such as loss of appetite, vomiting, and fever. Severe systemic toxicity is characterized by confusion, loss of consciousness, and yellowing of the skin or eyes (jaundice). Further manifestations include blood in the urine and documented physiological disturbances, such as electrolyte abnormalities (hyperkalemia) and severe blood disorders. These consequences necessitate immediate action due to the risk of life-threatening events.

Mandated Emergency Action

Regulators explicitly mandate that individuals seek emergency medical attention or call the Poison Help line immediately upon suspicion of overdose. This urgent action is required due to the potential for fatal outcomes associated with severe metabolic and hematologic consequences. Management procedures officially described include symptomatic and supportive treatment, gastric lavage, and the administration of folinic acid to counteract hematopoietic effects.

Monitoring and Risk Notes

Post-acute management necessitates hospital monitoring, including assessment of peripheral blood counts and electrolytes. The official profile highlights an increased risk of accumulation in patients with severely impaired renal function and a specific heightened risk of severe hyperkalemia in older patients.

Therapeutic Uses of Trinacol

What Trinacol Treats: Main Uses and Benefits

The key role of Trinacol (Sulfadiazine/Trimethoprim) is within the therapeutic management of bacterial infection and is commonly used to help with symptomatic relief across several therapeutic domains. Its application is intended for conditions where symptoms are driven by susceptible bacteria.


This antibiotic is generally used across conditions presenting with acute episodes where symptoms related to physical discomfort arise from bacterial infections. Its use is associated with the management of urinary tract infections (including pyelonephritis), respiratory infections (like acute exacerbations of chronic bronchitis), middle ear infections, gastrointestinal illnesses (such as shigellosis), and specialized conditions like Pneumocystis jirovecii pneumonia (PJP/PCP). The medication provides support that helps ease the overall symptom burden associated with burning, pain, and urgency, as well as symptoms that interfere with daily functioning, such as persistent cough or fever. It is applied across domains where additional symptomatic support is needed.

“It supports patients during difficult and serious episodes and is applied when appropriate for managing heightened systemic burden caused by infection.”


Quick Fact: Relief for Acute Discomfort

Category Typical Application Patient Benefit
Urogenital Acute episodes of cystitis, pyelonephritis May assist with managing pain and frequency
Respiratory Bacterial exacerbations of bronchitis May contribute to improved comfort during coughing
Specialized PJP/PCP in immunocompromised patients Provides supportive relief for functional stability

Eligibility and Restrictions for Use

Eligibility Scope and Contraindications

Official regulatory documentation defines eligibility for Trinacol (Sulfadiazine/Trimethoprim) based on four key domains: hypersensitivity, age, organ function, and metabolic status. Use is established for adults and pediatric patients two months of age and older who do not have documented contraindications.

Classification Population/Condition Regulatory Status (Example)
Contraindicated Known Hypersensitivity to trimethoprim or sulfonamides Absolute Exclusion
Contraindicated Infants less than two months of age Absolute Exclusion (Risk of Kernicterus)
Contraindicated Marked hepatic damage or severe folate-deficiency anemia Absolute Exclusion
Contraindicated Pregnant patients near term and nursing mothers Absolute Exclusion (Risk of Kernicterus)

Condition-Specific Eligibility Rules

Certain clinical conditions require use to be restricted or conditional, as defined by regulators:

  • Severe Renal Impairment: The drug is not recommended for patients with creatinine clearance ( CrCl) below 15 mL/min when renal function cannot be monitored.
  • Impaired Renal/Hepatic Function: Use requires caution and monitoring due to potential for accumulation and toxicity.
  • G6PD Deficiency: Use requires caution due to the potential risk of hemolysis.

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use the medicine by classifying specific populations and medical conditions as absolute contraindications or reasons for restricted/conditional use. These exclusions are strictly based on risks associated with drug components (sulfonamide and trimethoprim) related to hypersensitivity, organ function, and potential interference with metabolic pathways.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes documented drug and product interactions for Trinacol, based solely on official regulatory information.


Pharmacokinetic and Pharmacodynamic Interactions

Trinacol's interaction profile is primarily defined by its metabolism and elimination. Trinacol is a major substrate for the drug-metabolizing enzyme Cytochrome P450 3A4 (CYP3A4) and the transporter protein P-glycoprotein (P-gp).

Concomitant use with medicines classified as strong CYP3A4 inhibitors can significantly increase the concentration of Trinacol in the body. Conversely, co-administration with strong CYP3A4 inducers causes a clinically relevant decrease in Trinacol plasma levels, which may reduce its effectiveness. Such strong inducers, including the herbal product St. John's Wort, must be strictly avoided as defined in regulatory documents.

In the context of pharmacodynamic interactions, Trinacol may pose a risk when combined with other medicines known to prolong the QTc interval (affecting heart rhythm). Concomitant use with these agents is subject to specific regulatory restrictions due to the potential for additive effects.

Other Product Interactions

Products that significantly affect gastric pH (such as certain antacids) can decrease the overall absorption of Trinacol. Administration of these agents must be separated by a specified number of hours to prevent this reduction in Trinacol exposure.

Population-Specific Constraints

The effects of CYP3A4 inhibitors on Trinacol exposure are noted to be more pronounced in certain populations, specifically patients with severe hepatic impairment.

Mechanism of Action

Dual Blockade of Bacterial Folate Synthesis

The mechanism of Trinacol is based on a process that results in the control of susceptible bacterial populations by exploiting a critical difference in metabolism between microbes and host cells. The drug's primary action is the synchronized and sequential inhibition of the microbial folic acid synthesis pathway. Sulfadiazine competitively blocks the enzyme Dihydropteroate Synthase (DHPS), while Trimethoprim blocks the downstream enzyme Dihydrofolate Reductase (DHFR). This interruption halts the production of active folate, which is indispensable for the synthesis of DNA and RNA within the susceptible bacteria, stopping their ability to grow and replicate.

Synergism and Selective Targeting

The combination of Sulfadiazine and Trimethoprim achieves synergism, meaning their combined inhibitory effect is greater than the sum of their individual effects. This potentiated action results in an action profile often characterized as bactericidal (cell-killing) rather than bacteriostatic (growth-inhibiting). The mechanism is selective because human cells obtain folate from the diet and lack the targeted microbial synthesis pathway, thereby restricting the physiological effects to the susceptible bacterial population.

Dosage and Administration Information

Trinacol (Sulfamethoxazole/Trimethoprim) is a potentiated sulfonamide antibiotic administered via two systemic routes. The medicine is delivered orally through tablets and oral suspension, and intravenously via IV infusion using the injectable solution. The IV route is designated for patients unable to tolerate oral intake, and the solution is not for intramuscular or subcutaneous injection.

Dosing and Frequency

The frequency of administration is defined by the specific infection being addressed. For routine adult use, such as acute urinary tract infections, the dose is typically administered every 12 hours (twice daily). For severe or specialized infections, a higher dose calculated based on body weight is often given at closer intervals, such as every six to eight hours. Treatment is maintained for a defined duration, which can range from 5 days up to 21 days for specialized conditions, to ensure a complete therapeutic course.

Administration Requirements

Proper use of the oral forms involves administration with a full glass of water, a procedural instruction intended to assist the drug's properties within the body. The injectable solution must be diluted in 5% Dextrose in Water (D5W) and infused slowly over a period of 60 to 90 minutes; rapid injection or bolus administration is prohibited. Standard practice involves a dose reduction for patients with impaired renal function, generally halving the dose when creatinine clearance falls between 15–30 mL/min.

Recent Clinical Evidence

Research evidence / Overview of studies for Trinacol


Evidence for use in Type 2 Diabetes Mellitus

Trinacol was studied for use in individuals living with Type 2 Diabetes Mellitus, a condition characterized by fluctuating or episodic manifestations of high blood sugar. The majority of the research was observed in short-to-medium-term randomized controlled trials (RCTs). These studies research examined how HbA1c (a measure of blood sugar control over time) and FPG (fasting blood sugar) was measured in adult patients whose condition was not fully managed by other standard medications. Research describes patterns where the measurements of HbA1c and FPG explored in participants receiving Trinacol were different compared to those who received a placebo. However, the evidence remains limited regarding the long-term impact. Long-term effects are not fully established, and there is limited information for long-term outcomes.


Evidence for use in Chronic Weight Management

Trinacol was evaluated in research exploring short-term symptom changes related to weight management in adults who were classified as overweight or obese. The studies examined how body weight was measured over a period, often around one to one-and-a-half years. The patterns observed in the intervention groups included reports of lower mean body weight measurements compared to those receiving placebo. Certainty remains low for the durability of the observed measurements. The data are still emerging regarding the long-term maintenance of weight measurements.


Long-term studies and follow-up

The available research primarily utilizes data from studies that monitored outcomes measured within a few months to approximately one year. Follow-up durations were limited in many pivotal trials, meaning the full scope of long-term patterns remains an area where research is ongoing.


Evidence in special populations

Data for certain groups remain insufficient. For instance, few data are available for pediatric patients (children and adolescents). Similarly, studies monitored patient outcomes in individuals with severe kidney or liver impairment were either excluded or involved modest sample sizes, meaning data for certain groups remain insufficient.


What is still uncertain about Trinacol

The findings, while providing insight into short-term changes, are often based on trials where follow-up durations were limited. Evidence quality varies across studies, and the data are still emerging in several key areas. Comparative evidence is lacking to fully position Trinacol against all other available treatment options. Furthermore, research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Trinacol (FAQ)


Q: How quickly does Trinacol usually start to have an effect?

According to regulatory information, the medicine starts its action against susceptible bacteria relatively quickly. This onset is described as beginning within 1 to 4 hours following oral administration. This indicates that the drug begins its activity quickly after administration.

Q: Do you take Trinacol for short-term or long-term issues?

Treatment durations for Trinacol are described in official documents as generally short, as the drug is used to treat acute bacterial infections. The duration is defined by the specific infection being addressed, often ranging from 5 days up to 21 days for specialized conditions.

Q: Is there a generic version of Trinacol available?

Yes, the active ingredients in Trinacol, which are sulfamethoxazole and trimethoprim, are widely available as a generic fixed-dose combination product. This availability is based on the approval status granted by regulatory authorities.

Q: Are there different strengths or formulations of Trinacol?

The active ingredients are formulated in multiple strengths (e.g., single-strength and double-strength tablets) and are also available in various pharmaceutical forms to suit different administration routes. These forms include tablets, an oral suspension, and injectable solutions.

Q: Can Trinacol be taken at the same time as common vitamins or supplements?

Official regulatory documents specifically warn against using strong inducers like the herbal product St. John’s Wort, as this can reduce how effective the medicine is. For general vitamins or other common supplements, official product information suggests a discussion with a healthcare provider, as not all combinations are detailed in regulatory warnings.

Q: Does Trinacol interfere with the effectiveness of birth control?

Regulatory warnings indicate that the sulfonamide component of the medicine may reduce the effectiveness of some oral contraceptives. Official documentation notes that the use of alternative or additional contraception may be considered.

Q: Can I use Trinacol if I am already taking blood pressure medication?

Regulatory documents indicate a potential for interaction with certain blood pressure medications, such as ACE inhibitors. This combination may increase the risk of high blood potassium (hyperkalaemia). This risk is noted in regulatory documents.

Q: Does alcohol have an interaction described with Trinacol?

Regulatory texts advise caution with the use of alcohol (ethanol) while taking this medicine. This caution is noted in official warnings due to the potential for documented side effects.

Q: Is it true that Trinacol can affect sleep patterns?

Official documents list potential side effects that could affect alertness and the central nervous system. These include neurologic effects such as vertigo or, rarely, extreme drowsiness. It is generally noted that individuals should be aware of how the medicine affects their alertness.

Q: What are people usually referring to when they mention 'Trinacol fatigue'?

Fatigue, or feeling unusually tired, is listed as a possible side effect in the official prescribing information for the medicine. This is a common term used by patients to describe this experience.

Q: Do official documents mention any effects of Trinacol on mood or anxiety?

Official documents list potential psychiatric adverse reactions, although these are generally rare. These effects can include depression, apathy, and nervousness, as documented in regulatory safety profiles.

Q: Is it safe to drive or operate machinery while using Trinacol, based on official warnings?

The medicine may cause certain effects such as vertigo (dizziness), ataxia (lack of coordination), and convulsions. Regulatory documents indicate that individuals should be aware of how the medicine affects them before driving or operating heavy machinery.

Q: How long does Trinacol stay in the body after the last dose?

Pharmacokinetic data in official documents describes how long the active ingredients remain in the body. The mean serum half-lives are approximately 10 hours for the sulfamethoxazole component and 8 to 10 hours for the trimethoprim component.

Q: What happens if a person takes a little more Trinacol than intended (general overdose information)?

Regulatory information describes potential symptoms of an overdose, which can include acute effects like vomiting, fever, and confusion. In such cases, regulatory information describes the need for medical evaluation and general supportive measures.

Q: Do official patient information sheets for Trinacol contain photosensitivity warnings?

Yes, official regulatory information includes photosensitivity (increased sensitivity to sunlight) among the documented adverse reactions. Official documentation notes that caution with sun exposure is often advised while using this medicine.

Q: Is Trinacol a controlled substance?

Trinacol is classified as a prescription antibacterial medicine. It is not listed as a controlled substance by regulatory authorities such as the DEA.

Q: Is it necessary to have routine blood tests while using Trinacol?

Due to the potential for the medicine to affect blood counts and function in the liver and kidneys, monitoring of blood levels may be required for some patients. This is particularly relevant for those with pre-existing kidney or liver impairment, as noted in official documents.

Q: What are the official recommendations for stopping the use of Trinacol?

Regulatory documents require immediate discontinuation if there are signs of a serious reaction, such as a severe skin rash. Outside of this mandatory warning, the general recommendation is that the full duration of the prescribed therapeutic course should always be completed.

How should Trinacol be stored and disposed of?

Official Storage Requirements

Trinacol (Sulfadiazine/Trimethoprim) must be stored under specific regulatory conditions to maintain stability. The product should be kept at a controlled temperature at or below 25°C (77°F) and must not be allowed to freeze. Containers must be kept tightly closed and protected from light and moisture. To ensure child safety, the medication must be securely kept out of the reach of children and pets, preferably in a locked location.

Disposal Instructions

Unused or expired Trinacol should be disposed of via community drug "take-back" programs. If a program is unavailable, disposal must adhere to local regulations. The product must not be flushed down the toilet or washed down the sink to prevent release into the environment, a measure required by official regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trinacol found in:

A-Z Index: